Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
Objective: To evaluate annual concomitant psychotropic medication use among stimulant-treated children/adolescents with ADHD. Method: Children/adolescents with ≥1 primary ADHD diagnosis who had received ≥30 days of stimulant medication were identified from insurance claims for each calendar year (20...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939321/ https://www.ncbi.nlm.nih.gov/pubmed/29991300 http://dx.doi.org/10.1177/1087054718784668 |
_version_ | 1783484193797308416 |
---|---|
author | Zhou, Zhou Betts, Keith A. Bocharova, Iryna Kinrich, David Spalding, William M. |
author_facet | Zhou, Zhou Betts, Keith A. Bocharova, Iryna Kinrich, David Spalding, William M. |
author_sort | Zhou, Zhou |
collection | PubMed |
description | Objective: To evaluate annual concomitant psychotropic medication use among stimulant-treated children/adolescents with ADHD. Method: Children/adolescents with ≥1 primary ADHD diagnosis who had received ≥30 days of stimulant medication were identified from insurance claims for each calendar year (2011-2014). Use of 15 psychotropic medications concomitantly with stimulants was evaluated and their prevalence in each year was calculated overall and by medication category for children (6-12 years) and adolescents (13-17 years). Results: Each year 133,354 to 157,303 children and 95,632 to 111,280 adolescents were included. Annual period prevalence of any concomitant psychotropic medication use was 22.9% to 25.0% for children and 25.2% to 28.2% for adolescents. The most common medication categories included selective serotonin reuptake inhibitors (children: 6.8%-7.9%; adolescents: 12.7%-14.9%), atypical antipsychotics (4.2%-5.4%; 5.3%-6.3%), and guanfacine extended release (5.1%-7.0%; 2.3%-3.6%). Conclusion: Around a quarter of children/adolescents with ADHD were prescribed psychotropic medication concomitant to stimulant treatment, although only 2 of the 15 medication classes studied were Food and Drug Administration (FDA)-approved for adjunctive use. |
format | Online Article Text |
id | pubmed-6939321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69393212020-02-07 Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States Zhou, Zhou Betts, Keith A. Bocharova, Iryna Kinrich, David Spalding, William M. J Atten Disord Articles Objective: To evaluate annual concomitant psychotropic medication use among stimulant-treated children/adolescents with ADHD. Method: Children/adolescents with ≥1 primary ADHD diagnosis who had received ≥30 days of stimulant medication were identified from insurance claims for each calendar year (2011-2014). Use of 15 psychotropic medications concomitantly with stimulants was evaluated and their prevalence in each year was calculated overall and by medication category for children (6-12 years) and adolescents (13-17 years). Results: Each year 133,354 to 157,303 children and 95,632 to 111,280 adolescents were included. Annual period prevalence of any concomitant psychotropic medication use was 22.9% to 25.0% for children and 25.2% to 28.2% for adolescents. The most common medication categories included selective serotonin reuptake inhibitors (children: 6.8%-7.9%; adolescents: 12.7%-14.9%), atypical antipsychotics (4.2%-5.4%; 5.3%-6.3%), and guanfacine extended release (5.1%-7.0%; 2.3%-3.6%). Conclusion: Around a quarter of children/adolescents with ADHD were prescribed psychotropic medication concomitant to stimulant treatment, although only 2 of the 15 medication classes studied were Food and Drug Administration (FDA)-approved for adjunctive use. SAGE Publications 2018-07-10 2020-01 /pmc/articles/PMC6939321/ /pubmed/29991300 http://dx.doi.org/10.1177/1087054718784668 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Articles Zhou, Zhou Betts, Keith A. Bocharova, Iryna Kinrich, David Spalding, William M. Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
title | Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
title_full | Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
title_fullStr | Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
title_full_unstemmed | Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
title_short | Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
title_sort | concomitant use of psychotropic medication with stimulants for the treatment of adhd in children and adolescents: a retrospective insurance claims study in the united states |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939321/ https://www.ncbi.nlm.nih.gov/pubmed/29991300 http://dx.doi.org/10.1177/1087054718784668 |
work_keys_str_mv | AT zhouzhou concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates AT bettskeitha concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates AT bocharovairyna concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates AT kinrichdavid concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates AT spaldingwilliamm concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates |